Lynx1 Capital Management LP Stoke Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 5,291,929 shares of STOK stock, worth $69.3 Million. This represents 13.01% of its overall portfolio holdings.
Number of Shares
5,291,929
Previous 5,187,191
2.02%
Holding current value
$69.3 Million
Previous $57.2 Million
38.49%
% of portfolio
13.01%
Previous 22.22%
Shares
6 transactions
Others Institutions Holding STOK
# of Institutions
137Shares Held
56.6MCall Options Held
5.6KPut Options Held
142K-
Black Rock Inc. New York, NY5.41MShares$70.9 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$67.1 Million0.56% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$60.7 Million0.37% of portfolio
-
Redmile Group, LLC San Francisco, CA4.49MShares$58.8 Million3.13% of portfolio
-
Morgan Stanley New York, NY3.59MShares$47 Million0.0% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $516M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...